Eterna Therapeutics (ERNA)
4.31
-0.22 (4.86%)
Upcoming Events
Latest Headlines
Form 3 Ernexa Therapeutics Inc. For: Aug 04 Filed by: Polinsky David
August 27, 2026 7:53 PM - SEC Filing
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
August 27, 2026 9:01 AM - Globe NewsWire
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
August 27, 2026 9:01 AM - StreetInsider
Ernexa Therapeutics adds David Polinsky to its board of directors
August 10, 2026 9:02 AM - StreetInsider
Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
August 10, 2026 9:01 AM - StreetInsider
Form 10-Q Ernexa Therapeutics Inc. For: Jun 30
August 6, 2026 5:31 PM - SEC Filing
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
July 24, 2026 9:20 AM - Globe NewsWire
Three Biotechs Deliver Catalysts to Watch
July 15, 2026 10:43 AM - StreetInsider
Ernexa's ERNA-101 combo shows tumor clearance in animal study
July 15, 2026 7:50 AM - StreetInsider
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
July 15, 2026 7:50 AM - StreetInsider
Ernexa targets Q4 2026 for first-in-human ovarian cancer trial
July 14, 2026 9:01 AM - StreetInsider
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
July 14, 2026 9:01 AM - StreetInsider
Form 8-K Ernexa Therapeutics Inc. For: Jul 02
July 2, 2026 4:41 PM - SEC Filing
Form 8-K Ernexa Therapeutics Inc. For: Jul 01
July 2, 2026 4:31 PM - SEC Filing
Form 8-K Ernexa Therapeutics Inc. For: Jun 22
June 26, 2026 4:31 PM - SEC Filing
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
June 25, 2026 9:15 AM - StreetInsider
Ernexa Therapeutics plans IND filing for cancer cell therapy in Q3 2026
June 17, 2026 8:48 AM - StreetInsider
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
June 17, 2026 8:47 AM - StreetInsider
Ernexa highlights ovarian cancer treatment challenges in investor segment
June 9, 2026 8:41 AM - StreetInsider
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
June 9, 2026 8:41 AM - StreetInsider
Full Article List
